Device developer and manufacturer H&T Presspart and particle engineering/spray drying specialist Hovione have announced an expansion of their existing relationship with an agreement for development of H&T Presspart’s new Sunriser DPI technology. The two companies have previously partnered on development of the PowdAir Plus capsule-based dry powder inhaler.
According to the announcement, H&T Presspart will continue to be responsible for development and manufacturing of the the Sunriser device, which they describe as “flexible” and able to deliver both traditional carrier-based dry powder formulations and “an increasing variety of dry powder formulations, new particle engineering and powder processing methods,” including those manufactured by spray drying.
H&T Presspart President Christian Krätzig commented, “Following our successful collaboration with Hovione on the PowdAir Plus DPI device development, we are once again extremely pleased to be working with Hovione in developing this next generation high performance DPI device. As the market leader in respiratory components and devices, this strategic partnership will allow H&T Presspart to expand its portfolio within the growing field of dry powder technology.”
Hovione CEO Jean-Luc Herbeaux said, “New inhalable therapies are often requiring delivery of higher doses of cohesive and sensitive powders. Our priority is to ensure maximum efficiency in delivering these drugs to the right locations in the lung. We are thrilled to expand our current partnership with H&T Presspart and combine our expertise in the fields of engineered particles and inhalers for the benefit of our customers and patients.”
Read the H&T Presspart and Hovione press release.
